A study of BI 764198 for people with FSGS kidney disease
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if a new medicine called BI 764198 can help people with a kidney condition called FSGS. It looks at whether the drug can reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years old or older and weigh at least 40 kg (about 88 pounds).
- You must have a diagnosis of primary FSGS (confirmed by kidney biopsy) or a specific genetic form of FSGS (TRPC6 gain-of-function mutation).
- Your urine protein level must be high (UPCR 1500 mg/g or more) based on a urine test.
- Your kidney function (eGFR) must be at least 25, which shows moderately reduced but not severely damaged kidneys.
- You cannot have had a kidney transplant or be planning one, and you cannot have had certain strong immune-suppressing drugs in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
This trial tests whether the diabetes drug metformin can help people with a kidney disease called FSGS, by activating a cell-protecting pathway. Participants will take metformin or a placebo along with their usual steroid treatment.
This trial tests an investigational drug called praliciguat for people with FSGS, a kidney disease that causes scarring in the kidney filters. The goal is to see if praliciguat can help reduce protein in the urine and protect kidney function.
This study looks at how well a specialized blood-filter device (the LIPOSORBER® LA-15) works for people with primary FSGS—especially when standard steroid and other medicines don’t work or can’t be tolerated. It may help reduce disease activity, particularly in people with kidney function that is still moderate or in those after kidney transplant.
This trial studies a medical device (the Liposorber LA-15) in children with focal segmental glomerulosclerosis (FSGS), a kidney condition that can cause heavy protein loss in the urine. It may help by improving disease control when standard treatments have not worked, were hard to tolerate, or can’t be used.
This study tests an investigational drug (BI 764198) in adults and teens with different types of kidney disease. The goal is to see if the drug can help slow kidney damage. You may be able to join if your kidney function is at a certain level, you are on stable blood pressure medications, and you haven't had recent strong immune treatments.
Hear when a new Focal Segmental Glomerulosclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.